High Growth Tech Stocks in the US Market to Watch

As the U.S. market experiences fluctuations with the Dow retreating from record highs and investors keenly watching Nvidia's earnings amidst broader economic signals, tech stocks remain a focal point for many due to their potential for rapid growth and innovation. In such a dynamic environment, identifying high-growth tech stocks involves looking at companies that demonstrate strong fundamentals, adaptability to market changes, and robust prospects in emerging technologies like AI.

Name	Revenue Growth	Earnings Growth	Growth Rating
ACADIA Pharmaceuticals	10.87%	25.66%	★★★★★☆
ADMA Biologics	20.60%	23.25%	★★★★★☆
Palantir Technologies	25.25%	31.57%	★★★★★★
Workday	11.49%	29.77%	★★★★★☆
Circle Internet Group	27.36%	78.79%	★★★★★☆
OS Therapies	57.14%	70.11%	★★★★★☆
RenovoRx	65.52%	68.83%	★★★★★☆
Vanda Pharmaceuticals	22.66%	59.11%	★★★★★☆
Gorilla Technology Group	27.68%	129.58%	★★★★★☆
Aldeyra Therapeutics	42.88%	74.81%	★★★★★☆

Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that develops and commercializes vaccines both in the United States and internationally, with a market cap of approximately $1.23 billion.

Operations: The company generates revenue primarily from the discovery, development, and commercialization of novel vaccines, amounting to $316.27 million.

Dynavax Technologies has recently showcased robust growth and strategic advancements, particularly in its innovative vaccine development. The company's recent positive trial results for its novel shingles vaccine candidate, Z-1018, against the industry standard Shingrix, underscore a promising trajectory in vaccine efficacy and tolerability. Financially, Dynavax raised its 2025 revenue guidance to between $315 million and $325 million following strong first-half performance. This upward revision aligns with a significant 29.64% increase in Q2 revenue year-over-year, highlighting effective execution despite broader market challenges. Moreover, the firm's strategic decisions are set against a backdrop of increased R&D investments aimed at bolstering its competitive edge in the high-stakes biotech sector.

DVAX Earnings and Revenue Growth as at Aug 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exelixis, Inc. is an oncology company dedicated to discovering, developing, and commercializing new medicines for challenging cancer treatments in the United States, with a market cap of approximately $10.40 billion.

Operations: Exelixis focuses on the biotechnology segment, generating approximately $2.23 billion in revenue from its cancer treatment medicines.

Exelixis has demonstrated resilience with a 72.1% earnings growth over the past year, surpassing its industry's average. Despite a recent dip in quarterly revenue to $568.26 million from $637.18 million, the company maintains a robust forecast with annual revenues expected between $2.25 billion and $2.35 billion for 2025, underpinned by strategic share repurchases totaling $500 million this year alone. Innovatively, Exelixis's zanzalintinib shows promising clinical outcomes in colorectal cancer trials, potentially enhancing its portfolio and market position within oncology therapeutics—a sector marked by high stakes and rapid innovation cycles.

EXEL Revenue and Expenses Breakdown as at Aug 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Phreesia, Inc. offers a comprehensive SaaS-based software and payment platform tailored for the healthcare sector across the United States and Canada, with a market cap of approximately $1.81 billion.

Operations: Phreesia generates revenue primarily from its healthcare software segment, which accounted for $434.53 million. The company's business model focuses on providing integrated solutions to the healthcare industry in North America, leveraging its SaaS-based platform to enhance operational efficiency and patient engagement.

Phreesia, despite not being profitable yet, is on a path to profitability within the next three years, supported by an impressive expected annual earnings growth of 70.88%. This growth trajectory is bolstered by strategic collaborations such as the recent partnership with Sesame Workshop, which leverages Phreesia's digital intake platform to deliver educational content at pediatric healthcare visits. This initiative not only enhances client engagement but also positions Phreesia at the intersection of healthcare and digital innovation. Moreover, with a revenue growth forecast of 10.5% per year—surpassing the US market average—Phreesia is making significant strides in capturing market share while investing in future capabilities.

PHR Revenue and Expenses Breakdown as at Aug 2025

Unlock our comprehensive list of 67 US High Growth Tech and AI Stocks by clicking here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DVAX EXEL and PHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com